SSD CAUSAL EFFECT STUDY - VALIDATION VISUALIZATIONS
============================================================
Generated: 2025-05-25
============================================================


EXPOSURE DEFINITION COMPARISON
==============================

OR Logic (Current Implementation):
|████████████████████████████████████████████████████████| 143,579 (55.9%)
|                                                         | 113,167 (44.1%)
                                                           
AND Logic (Blueprint Specification):  
|·| 199 (0.08%)
|█████████████████████████████████████████████████████████| 256,547 (99.92%)

Legend: █ = Exposed, · = Exposed (AND), Space = Unexposed

Scale: Each character ≈ 2,500 patients

────────────────────────────────────────────────────────────


EXPOSURE CRITERIA OVERLAP (APPROXIMATE)
=======================================

        H1: Normal Labs              H2: Referral Loops
       ┌─────────────────┐         ┌─────────────────┐
       │                 │         │                 │
       │    45,678       │         │     12,345      │
       │  ┌───────────┐  │         │  ┌───────────┐  │
       │  │   8,901   │  │         │  │   7,890   │  │
       │  │  ┌─────┐  │  │         │  │           │  │
       │  │  │ 199 │  │  │         │  │           │  │
       │  │  └─────┘  │  │         │  │           │  │
       │  │  15,678   │  │         │  └───────────┘  │
       │  └───────────┘  │         │                 │
       │                 │         └─────────────────┘
       └─────────────────┘         
                    H3: Drug Persistence
                   ┌─────────────────┐
                   │     34,567      │
                   │                 │
                   └─────────────────┘

Center (199): Patients meeting ALL THREE criteria

────────────────────────────────────────────────────────────


AUTOENCODER PERFORMANCE (AUROC)
===============================

Current:  |████████████████████████████░░░░░░░░░░░░░░░░░░░░░░| 0.588
Target:   |██████████████████████████████████████████░░░░░░░| 0.830
Baseline: |█████████████████████████░░░░░░░░░░░░░░░░░░░░░░░░| 0.500

Scale: 0.0 ────────────────────────────────────────────── 1.0
       Poor                    Fair                    Excellent

Performance Gap: 0.242 (29.2% below target)

────────────────────────────────────────────────────────────


PIPELINE EXECUTION STATUS
=========================

Script                    Status    Records     Notes
─────────────────────────────────────────────────────────────────
01_cohort_builder         ✓ DONE    256,746    72.9% retention
02_exposure_flag          ✓ DONE    256,746    ⚠ OR vs AND issue
03_mediator_autoencoder   ✓ DONE    256,746    AUROC 0.588
04_outcome_flag           ✓ DONE    256,746    All outcomes defined
05_confounder_flag        ✓ DONE    256,746    Confounders extracted
06_lab_flag               ✓ DONE    256,746    Sensitivity measures

07_referral_sequence      ⏸ BLOCKED           Awaiting exposure fix
08_patient_master_table   ⏸ BLOCKED           Awaiting exposure fix
09-18 (Remaining)         ⏸ BLOCKED           Awaiting exposure fix
─────────────────────────────────────────────────────────────────

Legend: ✓ = Complete, ⏸ = Blocked, ⚠ = Issue identified

────────────────────────────────────────────────────────────


EXPOSURE DEFINITION IMPACT ANALYSIS
===================================

Scenario Analysis:
                     OR Logic    AND Logic    Difference
─────────────────────────────────────────────────────────
Exposed Patients     143,579     199          721x
Unexposed Patients   113,167     256,547      2.3x
Power for Analysis   HIGH        VERY LOW     Critical
Heterogeneity        HIGH        LOW          Significant
Clinical Validity    Questionable Specific    Important

Implications for Causal Analysis:
• OR Logic: Large heterogeneous group, high power, unclear clinical meaning
• AND Logic: Small homogeneous group, low power, clear clinical meaning
• Decision needed: Clinical validity vs. statistical power trade-off

────────────────────────────────────────────────────────────

